Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Nektar Therapeutics (NASDAQ:NKTR)

11.11
Delayed Data
As of Sep 03
 -0.29 / -2.54%
Today’s Change
9.16
Today|||52-Week Range
17.53
-28.32%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.5B

Company Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its products includes of drug candidates of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. The company was founded in 1990 and is headquartered in San Francisco, CA.

Contact Information

Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco California 94158
P:(415) 482-5300
Investor Relations:
(415) 482-5585

Employees

Shareholders

Mutual fund holders84.37%
Other institutional22.45%
Individual stakeholders1.88%

Top Executives

Howard W. RobinPresident, Chief Executive Officer & Director
John NicholsonChief Financial Officer & Senior Vice President
Stephen K. DobersteinChief Scientific Officer & Senior Vice President
Ivan P. GergelChief Medical Officer & Senior VP-Drug Development
Gilbert M. LabrucherieSecretary, Senior Vice President & General Counsel